



Momenta Pharmaceuticals to Present at the Deutsche Bank Small Cap Growth Conference

CAMBRIDGE, Mass., Feb. 8 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Steven B. Brugger, Senior Vice President, Strategic Business Operations, will present at the Deutsche Bank Small Cap Growth Conference on Wednesday, February 15, 2006 at 9:30 am EST at the Ritz-Carlton, Naples, Florida. A live audio webcast of the presentation will be available on the "Investors" section of the Company's website located at <http://www.momentapharma.com>. A replay of the presentation will be posted on the Momenta website approximately thirty minutes after the event and will be available through March 15, 2006.

About Momenta:

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic versions of sugar-based and complex drug products. The Company's most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox®. Based on its understanding of complex sugars, Momenta has created a diversified pipeline of near-term product opportunities, novel development products and discovery candidates. Momenta was founded in 2001 and is headquartered in Cambridge, MA.

To receive additional information about Momenta, please visit our website at <http://www.momentapharma.com>.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Contact:

Michael A. Lawless
Momenta Pharmaceuticals, Inc.
617-395-5189

SOURCE Momenta Pharmaceuticals, Inc.